High Dose Steroid Therapy to Prevent Severe Hypoxia in COVID-19 Patients : A Potential Solution for Low Resource Clinical Setting
Copyright © 2020, Edara et al..
Coronavirus disease 2019 (COVID-19) can lead to severe respiratory failure; about 5%-10% of patients progress to severe pneumonia and respiratory distress, leading to multi-system failure. Dexamethasone helped to prevent mortality in COVID-19 patients. Low resource population in developing countries has limited access to critical care, but they do have access to oral and IV corticosteroids, anti-hyperglycemic agents, and anticoagulants. We report two patients with severe COVID-19 successfully treated with a high dose of methylprednisolone therapy. Early intervention with high dose corticosteroids in COVID-19 patients could be a solution for pacifying cytokine storms and reducing morbidity and mortality.
| Errataetall: |
CommentIn: Adv Respir Med. 2021;89(5):550-551. - PMID 34612506 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Cureus - 12(2020), 12 vom: 27. Dez., Seite e12330 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Edara, Lokesh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Acute respiratory distress syndrome (ards) |
|---|
| Anmerkungen: |
Date Revised 03.11.2021 published: Electronic CommentIn: Adv Respir Med. 2021;89(5):550-551. - PMID 34612506 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.7759/cureus.12330 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM32081727X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM32081727X | ||
| 003 | DE-627 | ||
| 005 | 20231225174429.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.7759/cureus.12330 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1069.xml |
| 035 | |a (DE-627)NLM32081727X | ||
| 035 | |a (NLM)33520528 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Edara, Lokesh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a High Dose Steroid Therapy to Prevent Severe Hypoxia in COVID-19 Patients |b A Potential Solution for Low Resource Clinical Setting |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 03.11.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a CommentIn: Adv Respir Med. 2021;89(5):550-551. - PMID 34612506 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Copyright © 2020, Edara et al. | ||
| 520 | |a Coronavirus disease 2019 (COVID-19) can lead to severe respiratory failure; about 5%-10% of patients progress to severe pneumonia and respiratory distress, leading to multi-system failure. Dexamethasone helped to prevent mortality in COVID-19 patients. Low resource population in developing countries has limited access to critical care, but they do have access to oral and IV corticosteroids, anti-hyperglycemic agents, and anticoagulants. We report two patients with severe COVID-19 successfully treated with a high dose of methylprednisolone therapy. Early intervention with high dose corticosteroids in COVID-19 patients could be a solution for pacifying cytokine storms and reducing morbidity and mortality | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a acute respiratory distress syndrome (ards) | |
| 650 | 4 | |a covid 19 | |
| 650 | 4 | |a high dose corticosteroids | |
| 650 | 4 | |a hypoxia | |
| 650 | 4 | |a sars cov-2 | |
| 700 | 1 | |a Suvvari, Tarun Kumar |e verfasserin |4 aut | |
| 700 | 1 | |a Kutikuppala, Lakshmi Venkata Simhachalam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cureus |d 2013 |g 12(2020), 12 vom: 27. Dez., Seite e12330 |w (DE-627)NLM24118083X |x 2168-8184 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2020 |g number:12 |g day:27 |g month:12 |g pages:e12330 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.7759/cureus.12330 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2020 |e 12 |b 27 |c 12 |h e12330 | ||